10072606AI enabled precision diagnostics for heart muscle diseases with hypertrophyClosedCollaborative R&DInnovate UK**Cardiomyopathy** is a disease that affects the heart muscle and can cause heart failure and sudden death. The most common genetic type of this disease is called hypertrophic cardiomyopathy, which thickens the heart. In the last few years, the first of new drugs and gene therapies have been developed to treat this disease more precisely. These are real breakthroughs - for the first time promising not just disease control, but cure, and potentially even prevention. However, to treat this disease effectively , doctors need to be able to diagnose it with greater certainty. Currently, doctors use complex scans to diagnose patients, but these scans don't take into account differences in sex, ethnicity, and body size, which can result in misdiagnosis and mistreatment. Researchers in London have developed artificial intelligence technology that can measure heart scans more accurately than human experts. By using this technology, they have created new personalized diagnostic criteria that take into account differences in sex, ethnicity, and body size. They have also developed blood tests to diagnose and predict the risk of hypertrophic cardiomyopathy, distinguish diseases that resemble it and to help doctors choose the right treatment. A UK company called Mycardium AI Ltd, founded by disease and AI experts from UCL, is using this technology to transform heart disease patient care. Currently focusing only on one sort of scan, MRI, they have already helped thousands of patients and are working with drug companies to develop new treatments. In a partnership with UCL, Imperial, and LYVA labs, Mycardium AI aims to apply their personalized diagnostic criteria to patients worldwide. This will be done using not just MRI, but also ultrasound (echo scans) and new highly precise blood tests. By doing so, they hope to improve the lives of tens of thousands of patients by providing better, earlier treatment that targets their specific needs. This will also streamline care and make society healthier, happier, and wealthier. They plan to deliver their technology through multiple channels to healthcare providers worldwide, helping to usher in a new era of precision diagnostics for cardiology.